Not All ‘Indeterminate’ HBV Is Equal: Specific Indeterminate Types Carry Markedly Higher Long‑Term HCC Risk
Posted inGastroenterology Infectious Diseases news

Not All ‘Indeterminate’ HBV Is Equal: Specific Indeterminate Types Carry Markedly Higher Long‑Term HCC Risk

A multinational cohort study of 1,986 patients with indeterminate chronic hepatitis B (CHB) shows large differences in long‑term hepatocellular carcinoma (HCC) risk by baseline indeterminate subtype and by phase transition, identifying subgroups that may benefit from earlier antiviral therapy and intensified surveillance.
Congenital CMV in Australia: Reported Cases Are a Small Fraction of Estimated Burden — Implications for Screening, Treatment, and Public Health
Posted inInfectious Diseases news Pediatrics

Congenital CMV in Australia: Reported Cases Are a Small Fraction of Estimated Burden — Implications for Screening, Treatment, and Public Health

National APSU surveillance (1999–2024) found 479 definite congenital CMV cases and dramatic under-ascertainment versus expected prevalence; symptomatic infants increasingly receive antivirals. Expanded surveillance, newborn screening, and clear treatment pathways are needed.
Sequential Pegylated Interferon after Bepirovirsen Lowers Relapse Risk in Chronic Hepatitis B: Insights from the B-Together Trial
Posted inClinical Updates Infectious Diseases news Specialties

Sequential Pegylated Interferon after Bepirovirsen Lowers Relapse Risk in Chronic Hepatitis B: Insights from the B-Together Trial

The B-Together phase IIb study demonstrates that sequential therapy with bepirovirsen followed by pegylated interferon-α-2a reduces post-treatment relapse in chronic hepatitis B patients on stable nucleos(t)ide analogue therapy, with enhanced responses in patients with lower baseline HBsAg levels.